Video and roundtable: New hepatitis C drugs Solvadi, Olysio improve care

New drugs offer significant advantages, but payers must define payment approaches for optimal utilization. Three key thought leaders discuss this and more in our exclusive roundtable.
» More

All-oral Hep C drug combo expedited toward market launch

The FDA has granted Bristol-Myers Squibb Company a Breakthrough Therapy Designation for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV). » More

EDITOR'S CHOICE

• Aetna CEO: ACA not a cure for waste, rising health costs

• EHR market grows while industry looks to leverage capabilities

• 5 growth strategies for health plans

• Bonus pay falls for Medicare stars

• Medicare hits plans with another 3% cut

Keep in touch with MHE

We value your input. Please send your comments and article ideas to Editor in Chief Julie Miller. [email protected].